1
|
Soltani S, Matin BK, Gouya MM, Zahraei SM, Moradi G, Chehri O, Soofi M, Moradinazar M, Shadmani FK, Kalantari M, Khajeha H, Emamian MH, Najafi F. A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran. BMC Public Health 2023; 23:1415. [PMID: 37488541 PMCID: PMC10364349 DOI: 10.1186/s12889-023-16265-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Accepted: 07/08/2023] [Indexed: 07/26/2023] Open
Abstract
BACKGROUND Regarding the paucity of evidence on the side effects of the booster dose of Oxford AstraZeneca vaccine in vaccinated people with Sinopharm or Sputnik V, we aimed to set up a cohort event monitoring (CEM) study to capture adverse events occurring in individuals who will receive the booster doses of AstraZeneca (either the first or second booster dose) following being vaccinated with Sinopharm or sputnik V vaccines in Iran. METHODS The present study is an active COVID-19 vaccine safety surveillance through an observational prospective cohort study that will be conducted in vaccination centers in Iran. The study will be conducted in twelve provinces of Iran. Study sites are vaccination centers where the AstraZeneca vaccine is administered to the cohort population. The study population includes all individuals who have received two doses of Sinopharm or Sputnik V vaccines and either the first or second booster dose of AstraZeneca according to the national guidelines for immunization in Iran in 2023. We are planning to include 30,000 eligible people in this study. Each individual will be followed up for 13 weeks after either the first or second booster dose of the AstraZeneca vaccine. Furthermore, convenience sampling is used to include participants in the present study. Participation in the study will be strictly voluntary. DISCUSSION With the planned study we will provide a valid epidemiological evidence to improve the understanding of the safety of the booster dose of the AstraZeneca and to better evaluate the effectiveness of public health interventions. This could help policy makers in managing the COVID-19 pandemic according to scientific evidence.
Collapse
Affiliation(s)
- Shahin Soltani
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Behzad Karami Matin
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Mohammad Mehdi Gouya
- Iranian Center for Communicable Diseases Control, Ministry of Health & Medical Education, Tehran, Iran
| | - Sayed Mohsen Zahraei
- Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Ghobad Moradi
- Social Determinant of the Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | - Omid Chehri
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Moslem Soofi
- Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Mehdi Moradinazar
- Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Fatemeh Khosravi Shadmani
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Mahsa Kalantari
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Hamidreza Khajeha
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Mohammad Hassan Emamian
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Farid Najafi
- Research Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
| |
Collapse
|
2
|
Enayatrad M, Mahdavi S, Aliyari R, Sahab-Negah S, Nili S, Fereidouni M, Mangolian Shahrbabaki P, Ansari-Moghaddam A, Heidarzadeh A, Shahraki-Sanavi F, Fateh M, Khajeha H, Emamian Z, Behmanesh E, Sheibani H, Abbaszadeh M, Jafari R, Valikhani M, Binesh E, Vahedi H, Chaman R, Sharifi H, Emamian MH. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infect Dis 2023; 23:150. [PMID: 36899326 PMCID: PMC10000357 DOI: 10.1186/s12879-023-08103-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 02/19/2023] [Indexed: 03/12/2023] Open
Abstract
BACKGROUND This study aimed to evaluate the reactogenicity effects of COVID-19 vaccines, used in Iran. METHODS At least 1000 people were followed up with phone calls or self-report in a mobile application within 7 days after vaccination. Local and systemic reactogenicities were reported overall and by subgroups. RESULTS The presence of one or more local and systemic adverse effects after the first dose of vaccines was 58.9% [(95% Confidence Intervals): 57.5-60.3)] and 60.5% (59.1-61.9), respectively. These rates were reduced to 53.8% (51.2-55.0) and 50.8% (48.8-52.7) for the second dose. The most common local adverse effect reported for all vaccines was pain in the injection site. During the first week after the first dose of vaccines, the frequency of the pain for Sinopharm, AZD1222, Sputnik V, and Barekat was 35.5%, 86.0%, 77.6%, and 30.9%, respectively. The same rates after the second dose were 27.3%, 66.5%, 63.9%, and 49.0%. The most common systemic adverse effect was fatigue. In the first dose, it was 30.3% for Sinopharm, 67.4% for AZD1222, 47.6% for Sputnik V, and 17.1% for Barekat. These rates were reduced to 24.6%, 37.1%, 36.5%, and 19.5%, in the second dose of vaccines. AZD1222 had the highest local and systemic adverse effects rates. The odds ratio of local adverse effects of the AZD1222 vaccine compared to the Sinopharm vaccine were 8.73 (95% CI 6.93-10.99) in the first dose and 4.14 (95% CI 3.32-5.17) in the second dose. Barekat and Sinopharm had the lowest frequency of local and systemic adverse effects. Compared to Sinopharm, systemic adverse effects were lower after the first dose of Barekat (OR = 0.56; 95% CI 0.46-0.67). Reactogenicity events were higher in women and younger people. Prior COVID-19 infection increased the odds of adverse effects only after the first dose of vaccines. CONCLUSIONS Pain and fatigue were the most common reactogenicities of COVID-19 vaccination. Reactogenicities were less common after the second dose of the vaccines. The adverse effects of AZD1222 were greater than those of other vaccines.
Collapse
Affiliation(s)
- Mostafa Enayatrad
- Clinical Research Development Unit, Bahar Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Sepideh Mahdavi
- Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Roqayeh Aliyari
- Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Sajad Sahab-Negah
- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Sairan Nili
- Department of Public Health, Faculty of Health, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | - Mohammad Fereidouni
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
| | - Parvin Mangolian Shahrbabaki
- Department of Critical Care, Razi Faculty of Nursing and Midwifery, Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran
| | | | - Abtin Heidarzadeh
- School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Fariba Shahraki-Sanavi
- Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Mansooreh Fateh
- Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hamidreza Khajeha
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Zahra Emamian
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Elahe Behmanesh
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hossein Sheibani
- Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Maryam Abbaszadeh
- Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Reza Jafari
- School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Maryam Valikhani
- Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Ehsan Binesh
- Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Hamid Vahedi
- Clinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Reza Chaman
- Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hamid Sharifi
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
| | - Mohammad Hassan Emamian
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.
| |
Collapse
|
3
|
Hosseinzadeh A, Sahab-Negah S, Nili S, Aliyari R, Goli S, Fereidouni M, Alami A, Shati M, Ahmadnezhad E, Mehravaran S, Fateh M, Khajeha H, Emamian Z, Behmanesh E, Mahdavi S, Enayatrad M, Mangolian Shahrbabaki P, Ansari-Moghaddam A, Heidarzadeh A, Shahraki-Sanavi F, Hashemi Shahri SM, Dehghan M, Amini Moridani M, Sheibani H, Abbaszadeh M, Jafari R, Valikhani M, Binesh E, Vahedi H, Chaman R, Khodashahi R, Amini M, Jabbari Azad F, Rezaeitalab F, Amel Jamehdar S, Eshraghi A, Sharifi H, Hashemi Bajgani SM, Mahdavi A, Jafarzadeh A, Farokhnia M, Ebrahimi S, Pardakhti A, Ghaderi E, Soltani H, Jadidoleslami S, Arianejad A, Gavili H, Moradveisi B, Motamedi D, Zare H, Kazemi T, Emamian MH. COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran. Bull World Health Organ 2022; 100:474-483. [PMID: 35923277 PMCID: PMC9306382 DOI: 10.2471/blt.22.288073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/20/2022] [Accepted: 05/23/2022] [Indexed: 11/27/2022] Open
Abstract
Objective To investigate the incidence of coronavirus disease 2019 (COVID-19) cases, hospitalizations and deaths in Iranians vaccinated with either AZD1222 Vaxzevria, CovIran® vaccine, SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) or Sputnik V. Methods We enrolled individuals 18 years or older receiving their first COVID-19 vaccine dose between April 2021 and January 2022 in seven Iranian cities. Participants completed weekly follow-up surveys for 17 weeks (25 weeks for AZD1222) to report their COVID-19 status and hospitalization. We used Cox regression models to assess risk factors for contracting COVID-19, hospitalization and death. Findings Of 89 783 participants enrolled, incidence rates per 1 000 000 person-days were: 528.2 (95% confidence interval, CI: 514.0-542.7) for contracting COVID-19; 55.8 (95% CI: 51.4-60.5) for hospitalization; and 4.1 (95% CI: 3.0-5.5) for death. Compared with SARS-CoV-2 Vaccine (Vero Cell), hazard ratios (HR) for contracting COVID-19 were: 0.70 (95% CI: 0.61-0.80) with AZD1222; 0.73 (95% CI: 0.62-0.86) with Sputnik V; and 0.73 (95% CI: 0.63-0.86) with CovIran®. For hospitalization and death, all vaccines provided similar protection 14 days after the second dose. History of COVID-19 protected against contracting COVID-19 again (HR: 0.76; 95% CI: 0.69-0.84). Diabetes and respiratory, cardiac and renal disease were associated with higher risks of contracting COVID-19 after vaccination. Conclusion The rates of contracting COVID-19 after vaccination were relatively high. SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions.
Collapse
Affiliation(s)
- Ali Hosseinzadeh
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Sajad Sahab-Negah
- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Sairan Nili
- Faculty of Health, Kurdistan University of Medical Sciences, Sanandaj, Islamic Republic of Iran
| | - Roqayeh Aliyari
- Ophthalmic Epidemiology Research Center, 7 Tir Square, Shahroud University of Medical Sciences, Shahroud 3614773947, Islamic Republic of Iran
| | - Shahrbanoo Goli
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Mohammad Fereidouni
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Islamic Republic of Iran
| | - Ali Alami
- Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Islamic Republic of Iran
| | - Mohsen Shati
- Department of Epidemiology, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Elham Ahmadnezhad
- National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Shiva Mehravaran
- School of Computer Mathematics and Natural Sciences, Morgan State University, Baltimore, United States of America
| | - Mansooreh Fateh
- Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Hamidreza Khajeha
- Ophthalmic Epidemiology Research Center, 7 Tir Square, Shahroud University of Medical Sciences, Shahroud 3614773947, Islamic Republic of Iran
| | - Zahra Emamian
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Elahe Behmanesh
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Sepideh Mahdavi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Mostafa Enayatrad
- Bahar Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | | | - Alireza Ansari-Moghaddam
- Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Islamic Republic of Iran
| | - Abtin Heidarzadeh
- School of Medicine, Guilan University of Medical Sciences, Rasht, Islamic Republic of Iran
| | - Fariba Shahraki-Sanavi
- Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Islamic Republic of Iran
| | - Seyed Mohammad Hashemi Shahri
- Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Islamic Republic of Iran
| | - Mahlagha Dehghan
- Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Islamic Republic of Iran
| | | | - Hossein Sheibani
- Imam Hossein Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Maryam Abbaszadeh
- Imam Hossein Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Reza Jafari
- School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Maryam Valikhani
- Imam Hossein Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Ehsan Binesh
- Imam Hossein Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Hamid Vahedi
- Imam Hossein Clinical Research Development Unit, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Reza Chaman
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Rozita Khodashahi
- Department of Infectious Diseases and Tropical Medicine, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Mahnaz Amini
- Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Farahzad Jabbari Azad
- Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Fariborz Rezaeitalab
- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Saeid Amel Jamehdar
- Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Ali Eshraghi
- Department of Cardiology, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Hamid Sharifi
- HIV/STI Surveillance Research Center, Kerman University of Medical Sciences, Kerman, Islamic Republic of Iran
| | | | - Amin Mahdavi
- Cardiovascular Research Centre, Kerman University of Medical Sciences, Kerman, Islamic Republic of Iran
| | - Abdollah Jafarzadeh
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran
| | - Mehrdad Farokhnia
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Faculty of Health, Kurdistan University of Medical Sciences, Sanandaj, Islamic Republic of Iran
| | - Saeedeh Ebrahimi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Ophthalmic Epidemiology Research Center, 7 Tir Square, Shahroud University of Medical Sciences, Shahroud 3614773947, Islamic Republic of Iran
| | - Abbas Pardakhti
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Islamic Republic of Iran
| | - Ebrahim Ghaderi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Islamic Republic of Iran
| | - Hasan Soltani
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Department of Epidemiology, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Sedigh Jadidoleslami
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Anoush Arianejad
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Hamed Gavili
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
| | - Borhan Moradveisi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,School of Computer Mathematics and Natural Sciences, Morgan State University, Baltimore, United States of America
| | - Dina Motamedi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Hamed Zare
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Islamic Republic of Iran
| | - Toba Kazemi
- School of Public Health, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran.,Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Islamic Republic of Iran
| | - Mohammad Hassan Emamian
- Ophthalmic Epidemiology Research Center, 7 Tir Square, Shahroud University of Medical Sciences, Shahroud 3614773947, Islamic Republic of Iran
| |
Collapse
|
4
|
Aliyari R, Mahdavi S, Enayatrad M, Sahab-Negah S, Nili S, Fereidooni M, Mangolian Shahrbabaki P, Ansari-Moghaddam A, Heidarzadeh A, Shahraki-Sanavi F, Amini Moridani M, Fateh M, Khajeha H, Emamian Z, Behmanesh E, Sharifi H, Emamian MH. Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. BMC Public Health 2022; 22:1153. [PMID: 35681132 PMCID: PMC9178529 DOI: 10.1186/s12889-022-13575-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 06/02/2022] [Indexed: 12/23/2022] Open
Abstract
Background New vaccines that are initially approved in clinical trials are not completely free of risks. Systematic vaccine safety surveillance is required for ensuring safety of vaccines. This study aimed to provide a protocol for safety monitoring of COVID-19 vaccines, including Sputnik V, Sinopharm (BBIBP-CorV), COVIran Barekat, and AZD1222. Methods This is a prospective cohort study in accordance with a template provided by the World Health Organization. The target population includes citizens of seven cities in Iran who have received one of the available COVID-19 vaccines according to the national instruction on vaccination. The participants are followed for three months after they receive the second dose of the vaccine. For each type of vaccine, 30,000 people will be enrolled in the study of whom the first 1,000 participants are in the reactogenicity subgroup. The reactogenicity outcomes will be followed seven days after vaccination. Any hospitalization, COVID-19 disease, or other minor outcomes will be investigated in weekly follow-ups. The data are gathered through self-reporting of participants in a mobile application or phone calls to them. The study outcomes may be investigated for the third and fourth doses of vaccines. Other long-term outcomes may also be investigated after the expansion of the follow-up period. We have planned to complete data collection for the current objectives by the end 2022. Discussion The results of this study will be published in different articles. A live dashboard is also available for managers and policymakers. All data will be available on reasonable requests from the corresponding author.The use of the good and comprehensive guidelines provided by WHO, along with the accurate implementation of the protocol and continuous monitoring of the staff performance are the main strengths of this study which may be very useful for policymaking about COVID-19 vaccination.
Collapse
Affiliation(s)
- Roqayeh Aliyari
- Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Sepideh Mahdavi
- Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Mostafa Enayatrad
- Clinical Research Development Unit, Bahar Hospital, Shahroud University of Medical Science, Shahroud, Iran
| | - Sajad Sahab-Negah
- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Sairan Nili
- Department of Public Health, Faculty of Health, Kurdistan University of Medical Sciences, Sanandaj, Iran
| | - Mohammad Fereidooni
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
| | - Parvin Mangolian Shahrbabaki
- Department of Critical Care, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
| | | | - Abtin Heidarzadeh
- School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Fariba Shahraki-Sanavi
- Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
| | | | - Mansooreh Fateh
- Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hamidreza Khajeha
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Zahra Emamian
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Elahe Behmanesh
- Health Technology Incubator Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Hamid Sharifi
- HIV/STI Surveillance Research Center, Kerman University of Medical Sciences, Kerman, Iran
| | - Mohammad Hassan Emamian
- Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.
| |
Collapse
|